Safety and Efficacy of Low Dose MM120 for ADHD Proof of Concept Trial
Safety and Efficacy of Repeated Low Dose d-Lysergic Acid Diethylamide (LSD) D-tartrate (MM120) as Treatment for ADHD in Adults: a Multi-center, Randomized, Double-blind, Placebo-controlled Phase 2a Proof of Concept Trial
Sponsor: Definium Therapeutics US, Inc.
A PHASE2 clinical study on ADHD and Attention Deficit Disorder, this trial is completed. The trial is conducted by Definium Therapeutics US, Inc. and has accumulated 9 data snapshots since 2021. Psychiatric clinical trials are essential for establishing evidence-based treatment standards.
Status Flow
Change History
9 versions recorded-
Feb 2026 — Present [monthly]
Completed PHASE2
-
May 2025 — Feb 2026 [monthly]
Completed PHASE2
-
Sep 2024 — May 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 4 earlier versions
-
Nov 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2023 — Nov 2023 [monthly]
Recruiting PHASE2
-
Jul 2022 — Sep 2023 [monthly]
Recruiting PHASE2
-
Feb 2022 — Jul 2022 [monthly]
Recruiting PHASE2
First recorded
Dec 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Definium Therapeutics US, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .